Oral Losartan in Prevention of Post-ERCP Paancreatitis

Ain Shams University100 enrolled

Overview

Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with another 50 patients underwent ERCP without receiving oral losartan.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

100

Conditions

Post-ERCP Acute Pancreatitis

Interventions

oral losatanDRUG

50 mg of oral losartan one hour before the ERCP once

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Any adult patient indicated for ERCP * Patients with obstructive jaundice. * Patients with dilated intra-hepatic or extra-hepatic bile ducts due to malignant or benign lesions. Exclusion Criteria: * Patients refusing to undergo the procedure or signing the informed consent * Patients with clinically evident acute pancreatitis before the procedure * Patients with previous endoscopic or surgical sphincterotomy * Patients with current use of losartan * Patients who are allergic or hypersensitive to losartan or hydro soluble contrast solutions * Patients receiving NSAIDS within a week prior to assessment * Patients with severe co-morbid conditions as cardiovascular disease, renal failure or decompensated liver cirrhosis.

Outcomes

Primary Outcomes

Number of participants with development of acute pancreatitis

Number of participants with development of abdominal pain and elevated serum amylase and/or lipase

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.